Figure 5 | Scientific Reports

Figure 5

From: Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

Figure 5

Co-treatment with AZD1775 and olaparib significantly inhibited tumor growth in our mouse xenograft model of MDA-MB-231 human breast cancer. (a) Treatment with AZD1775 plus olaparib significantly inhibited tumor growth the mouse model. Mice were treated with vehicle alone (n = 4), 60 mg/kg AZD1775 (n = 4), 40 mg/kg olaparib (n = 4), or both drugs (n = 5). Tumor volumes were measured three times weekly and are plotted with SE bars. ***P < 0.001. (b) Changes in mouse weights during the treatment period. Body weights were measured three times weekly. Bars, ± SEs. (c) Histological assessments of tumor response to AZD1775 alone and AZD1775 plus olaparib. The tumors were removed immediately after drug treatment, and pathologic examinations were conducted using hematoxylin and eosin (H&E) stained slides X20. Scale bars represent 50 μm. IHC staining for Ki-67 and a TUNEL assay were used to assess proliferation and apoptosis, respectively. AZD1775 reduced the level of p-CDK1(Tyr15). The scale bars represent 50 μm. Red arrows indicates each Ki-67, TUNEL, and p-CDK1(Tyr15) stained section.

Back to article page